Humana slides as 2026 earnings reset and Medicare Star Ratings headwind weighs
Humana shares fell about 3.45% to $168.71 as investors continued to reprice 2026 profitability after management projected at least $9.00 in 2026 adjusted EPS, well below prior expectations, citing a major Medicare Advantage Star Ratings headwind. The selloff has been reinforced by a drumbeat of cautious analyst actions and rating/price-target cuts tied to Medicare Advantage margin pressure.
1. What’s moving the stock
Humana stock traded lower today as the market continued to digest the company’s sharply reduced 2026 earnings power driven by Medicare Advantage Star Ratings pressure. Management previously set a conservative 2026 baseline of at least $9.00 in adjusted EPS, highlighting a large Stars-related headwind that compresses margins and lowers quality bonus payments, keeping the stock sensitive to any negative read-through on Medicare Advantage profitability. �citeturn1search3turn0search2turn0search101�
2. The fundamental overhang: Medicare Advantage quality and bonuses
The central issue remains Humana’s Medicare Advantage quality bonus trajectory. Lower Star Ratings reduce bonus payments and rebates that support benefits and margins, and the company has framed 2026 as a transition year while it works through the financial impact. Earlier legal setbacks tied to the ratings dispute also helped cement investor expectations for reduced 2026 profitability. �citeturn1search0turn1search4turn2search41�
3. Why the selling persists now
With the stock already reset from prior levels, incremental down days have often been driven by positioning and follow-on analyst recalibrations rather than a single fresh headline. Recent price-target reductions and downgrades have emphasized uncertainty around bid strategy, utilization trends, and the pace of margin recovery, extending skepticism into 2027. �citeturn1search5turn1search11turn1search101�
4. What to watch next
Investors are watching for evidence that medical-cost trends and pricing discipline can stabilize margins through 2026, plus any clarity on how quickly Humana can rebuild quality performance ahead of future Star Ratings cycles. Sector-wide Medicare Advantage policy signals also remain a swing factor for sentiment as the market tries to handicap forward reimbursement and risk-score dynamics. �citeturn1news12turn2search101�